English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17744/20032 (89%)
Visitors : 7308617      Online Users : 257
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/28685


    標題: Rosuvastatin Suppresses the Oxidative Response in the Venous Limb of an Arteriovenous Fistula and Enhances the Fistula Blood Flow in Diabetic Rats
    作者: Fang, Shih-Yuan
    Roan, Jun-Neng
    Lin, Yu
    Hsu, Chih-Hsin
    Chang, Shih-Wei
    Huang, Chein-Chi
    Tsai, Yu-Chuan
    Lam, Chen-Fuh
    貢獻者: 生物科技系
    關鍵字: HMG-CoA reductase inhibitors
    Inflammation
    Intimal hyperplasia
    Peripheral vascular diseases
    Superoxide
    Hennodialysis
    Arteriovenous shunt
    日期: 2014
    上傳時間: 2015-05-06 21:25:07 (UTC+8)
    出版者: Karger
    摘要: Objective:The blood flow in the arteriovenous (AV) fistula is significantly reduced in diabetic patients. Statins are known to mediate pleiotropic effects in the vascular endothelium and attenuate inflammatory responses. This study tested the vascular protective effect of rosuvastatin in an experimental model of AV fistula. Methods: One week after the induction of diabetes mellitus (DM) in rats, a fistula was created in the abdominal aorta and inferior vena cava. Rats received placebo or rosuvastatin (15 mg/kg/day) in chow for 2 weeks. The blood flow in the venous segments of the fistula was measured. The expression of proinflammatory genes and the generation of superoxide in the venous fistula were examined. Results: The blood flow and luminal diameter of the AV fistula was significantly enhanced in animals treated with rosuvastatin. Rosuvastatin attenuated the expression of inducible nitric oxide synthase, NADPH oxidase, and monocyte chemotactic protein-1 in the fistula. The levels of superoxide anions and proinflannmatory cytokines were also suppressed in rosuvastatin-treated animals. Neointinnal formation in the AV fistula was not affected following treatment with rosuvastatin. Conclusions: We demonstrated that rosuvastatin improves luminal dilatation and blood flow in the AV fistula of subjects with DM. These vascular protective effects of rosuvastatin are most likely mediated by the attenuation of proinflammatory activities in the remodeled vasculature. (C) 2014 S. Karger AG, Basel
    關聯: Journal of Vascular Research, v.51 n.2, pp.81-89
    Appears in Collections:[生物科技系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML493View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback